Navigation Links
Head-to-head study in RA shows that abatacept has comparable efficacy to adalimumab
Date:6/7/2012

Berlin, Germany, June 7 2012: Data from one of the few head-to-head trials in rheumatoid arthritis (RA) presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that at one year, 64.8% of patients receiving abatacept (Orencia) and 63.4% of patients receiving adalimumab (Humira) achieved ACR20*.

The Phase IIIb AMPLE study (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) was carried out in 646 biologic-nave patients with active RA and inadequate response to methotrexate. At four weeks, 42.5% of patients in the abatacept group achieved ACR20 response versus 47.6% in the adalimumab group. This remained comparable until the end of year one. At 12 months, ACR50* response was similar between the two groups (46.2% in the abatacept group and 46% in the adalimumab group). ACR70* response was 29.2% versus 26.2% in the abatacept group and adalimumab groups respectively. These data show the similar time course of response. Inhibition of radiographic progression was also similar in both arms.

"There have been very few head-to-head trials in rheumatoid arthritis and, to date, there have been no randomised, controlled studies directly comparing the safety and efficacy of different biologic disease-modifying anti-rheumatic drugs (DMARDs) using the combination of a biologic medication and methotrexate which is the most commonly prescribed treatment approach in moderate to severe RA," said Dr. Michael Schiff, University of Colorado, USA and lead author of the study. "This study is a great leap forward for us and our patients as it shows there is another treatment option that is as effective and as safe as adalimumab."

The AMPLE study is a randomised, investigator-blinded study of 24 months, with a 12 month efficacy primary endpoint. Patients were stratified by disease activity and randomised to either 125mg subcutaneous abatacept (without an IV load) w
'/>"/>

Contact: Candice Debleu
eularpressoffice@cohnwolfe.com
44-789-438-6425
European League Against Rheumatism
Source:Eurekalert

Page: 1 2

Related medicine news :

1. For Lung Disorder, Spiriva Beat Serevent in Head-to-Head Trial
2. Newer Drugs Beat Gleevec in Head-to-Head Trials
3. UT Southwestern investigators perform head-to-head comparison of incontinence treatments
4. Exercise Appears to Ease Nerve-Damage Pain in Rat Study
5. New Medicine Might Fight Drug-Resistant TB, Study Says
6. Exercise Controls Weight in White Girls Better Than in Black Girls: Study
7. Gout Flare-ups Rise Sharply With Certain Foods: Study
8. Dana-Farber: Study reports first success of targeted therapy in type of non-small cell lung cancer
9. Humans Can Sniff Out Old Age in Others, Study Shows
10. Infant Smarts Similar With Different Types of Formula: Study
11. Pre-op Treatments Boost Survival for Esophageal Cancer Patients: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Date: Thursday, June 4, 2015 , Time: 2 ... Broad Street, 4th floor, Philadelphia, Pa 19107 , ... will visit Philadelphia City Council to urge city leaders ... C in Philadelphia’s at-risk populations. , Foundation leaders and ... B United Philadelphia (HBUP), will join Hepatitis C Allies ...
(Date:6/2/2015)... June 02, 2015 While the movie ... of comic books, comic books themselves are stepping into ... Uniting Nations plans to produce educational comics in multiple ... Goals for Sustainable Development - an international effort to ... hunger, health, education, sustainable energy, inequality, climate change and ...
(Date:6/2/2015)... Join us for a new event in Westwood, ... Rhonda Martin , who overcame her brain aneurysm during the ... to raising awareness and funds for brain aneurysm research. ... that there will be one less case of someone suffering ... to join the 1st Anniversary Awareness Walk in Honor ...
(Date:6/2/2015)... June 02, 2015 Pacifica Graduate ... set up by current and former students to honor ... faculty member from 2002 until his death in 2013. ... and depth of feeling, as well as his passion ... capacities as an analyst, teacher, and writer were felt ...
(Date:6/2/2015)... June 02, 2015 “We want men to ... (UV) sun rays”, states Marta Phillips, owner of SunGrubbies.com, ... sun hats and sun accessories that work well for outdoor ... immediately evident. Sometimes sun damage can take up to thirty ... are prime areas for skin cancer to occur. That ...
Breaking Medicine News(10 mins):Health News:Hepatitis B Foundation to Urge Philadelphia Leaders to Make Viral Hepatitis Prevention a Local Priority 2Health News:Can Comics Help the United Nations Save the World? 2Health News:Can Comics Help the United Nations Save the World? 3Health News:New Awareness Raising Event in Westwood, NJ to Benefit Renowned Brain Aneurysm Foundation 2Health News:Pacifica Graduate Institute - Mythological Studies Students Establish Memorial Scholarship to Honor Dr. V. Walter Odajnyk 2Health News:Pacifica Graduate Institute - Mythological Studies Students Establish Memorial Scholarship to Honor Dr. V. Walter Odajnyk 3Health News:It is Time to Show Father Who Knows Best, Says SunGrubbies.com, a Leading Online Sun Protection Retailer 2
... HILLS, Mich., May 13 Fund-raising for disease,research got ... and,President Jim Press and his wife Suwichada presided as ... annual Promise Ball,in Dearborn, Mich., As part of ... presented to Cynthia and Edsel B. Ford II. The ...
... Encourages Women to ,Speak Up For Down There, During National ... ... Despite living in a society,that promotes images and icons of ... Dr. Sue Johannsen and even,former Supreme Court Justice Sandra Day O,Conner, ...
... post-university years can start out tough. The good news: ... study of almost 600 of its graduates (ages 20-29 ... seven years post-graduation and looked at how key events ... to depression and anger. Graduates showed a significant decrease ...
... 2008 The American Society for Gastrointestinal ... regarding gastrointestinal (GI) endoscopy. The guidelines note that ... the adoption of endoscope reprocessing (cleaning) guidelines. The ... issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed ...
... mechanism by which emerging daughter cells organize and divvy ... new study, researchers at the University of Illinois and ... orchestrates chromosome movements at a critical stage of cell ... the National Academy of Sciences. , Within the complex ...
... The rate of childhood,obesity in America has more ... of children ages 10 to 17 are overweight ... of the obesity epidemic for,children, families, communities and ... Healthy Florida ( http://www.bluefoundationfl.com ), the,philanthropic affiliate of ...
Cached Medicine News:Health News:Chrysler LLC Vice Chairman and President Jim Press and His Wife Suwichada Serve as Honorary Co-Chairs of Annual Juvenile Diabetes Research Foundation Promise Ball 2Health News:Study Finds More Than One in Two Women are Too Embarrassed to Discuss Vaginal Discomfort With Their Doctors 2Health News:Study Finds More Than One in Two Women are Too Embarrassed to Discuss Vaginal Discomfort With Their Doctors 3Health News:Study Finds More Than One in Two Women are Too Embarrassed to Discuss Vaginal Discomfort With Their Doctors 4Health News:Depression and anger can plague recent university graduates: Study 2Health News:ASGE issues updated infection control guidelines for gastrointestinal endoscopy 2Health News:ASGE issues updated infection control guidelines for gastrointestinal endoscopy 3Health News:Research shines spotlight on a key player in the dance of chromosomes 2Health News:Research shines spotlight on a key player in the dance of chromosomes 3Health News:The Blue Foundation for a Healthy Florida Announces $8 Million Initiative to Address Childhood Obesity 2
(Date:6/2/2015)... MADRID , June 2, 2015 /PRNewswire/ ...   10503), vorgestellt auf dem Jahrestreffen der ... PharmaMar teilt mit, dass Janssen Research ... multizentrischen Phase-3-Studie SAR3007 bekannt gegeben hat, ... (progression-free survival, PFS) mit Trabectedin (YONDELIS ® ...
(Date:6/1/2015)... 2, 2015 Amgen (NASDAQ: AMGN ... a Phase 1b study to evaluate the safety ... immunotherapy, in combination with Roche,s investigational anti-PDL1 therapy, ... triple-negative breast cancer and colorectal cancer with liver ... oncolytic immunotherapy designed to selectively replicate in tumors ...
(Date:6/1/2015)... June 1, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. ... with a focus on Omega-3 therapies for cardiovascular ... highlights and financial results for the three months ... herein are in Canadian dollars unless otherwise stated. ... business strategies despite its limited financial resources," stated ...
Breaking Medicine Technology:PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 2PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 3PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 4PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 5PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 2Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 3Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 4Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 5Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 7Pivotal Therapeutics Announces First Quarter Financial Results 2Pivotal Therapeutics Announces First Quarter Financial Results 3Pivotal Therapeutics Announces First Quarter Financial Results 4Pivotal Therapeutics Announces First Quarter Financial Results 5
... (Nasdaq: GNTA ) today announced financial results and progress,for ... noted,significant recent milestones, including:, -- ... -- New oral product, G4544, completes initial Phase ... -- Tesetaxel, a leading oral taxane, becomes new ...
... Committee Recommends FDA Approve Novel Anesthesia Drug to Reverse Muscle ... ... Schering-Plough,(NYSE: SGP ) today announced that the U.S. ... Support has recommended,sugammadex for approval. After reviewing data on the ...
Cached Medicine Technology:Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 2Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 3Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 4Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 5Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 6Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 7Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 8Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 9Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 10FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent 2FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent 3FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: